{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"9.100","floor":"8.300"},"ipodate":{"start":"2015-06-01 00:00:00","end":"2015-06-04 00:00:00"},"minimumcapital":"4596.00","subscribed":"201.57","marketcap":"220.62億","H_marketcap":"--","pe":"60.42","codesrate":"100.00","link":"https://staticpdf.iqdii.com/stockdata/notice/Prospectus/01530/LTN20150601156_C.pdf","ipopricing":"9.100","resultdate":"2015-06-10 00:00:00","enddate":"2015-06-04 00:00:00","listeddate":"2015-06-11 00:00:00","issuenumber":"60610.00萬","issuenumberhK":"24244.00萬","issuenumberother":"36366.00萬","grayprice":"9.35","sponsors":"中信證券融資(香港)有限公司,高盛(亞洲)有限責任公司,摩根士丹利亞洲有限公司","raisemoney":"417000.00萬","use":"1、約45%，或約1,876.5百萬港元，將用于通過選擇性收購擴大我們重點治療領域的藥物產品組合；\n2、約15%，或約625.5百萬港元，將用于透過聘額外銷售人員等方式加強我們產品的銷售及營銷；\n3、約15%，或約625.5百萬港元，將用于為資本開支項目融資，以透過興建新生產線提高我們的產能；\n4、約15%，或約625.5百萬港元，將用于為研發項目（包括內部研發項目及外部合作項目）融資；\n5、約10%，或約417.0百萬港元，將用于補充我們的營運資金及作一般公司用途。","shares":500,"leadagent":"摩根士丹利亞洲有限公司,中信里昂證券有限公司,高盛(亞洲)有限責任公司,中國國際金融香港證券有限公司,招商證券(香港)有限公司","bookrunners":"摩根士丹利亞洲有限公司,中信里昂證券有限公司,高盛(亞洲)有限責任公司,中國國際金融香港證券有限公司,招商證券(香港)有限公司","coordinator":"摩根士丹利亞洲有限公司,高盛(亞洲)有限責任公司,中信里昂證券有限公司,中國國際金融香港證券有限公司","firstDayOpen":"9.32","IsEiio":0,"Interestdays":6,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"高盛(亞洲)有限責任公司","code":"E01530","name":"三生制藥","fullname":"三生制藥"},"institutioninfo":{"principaloffice":"中國沈陽經濟技術開發區十號路1甲3號","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628","chairman":"婁競","secretary":"梁雪穎","telephone":"(8624) 2538 6000","substantialshareholders":"CITIC PE Funds Limited(24.54%),婁競及關連人士(23.67%),J.P. Morgan Chase & Co.(7.07%)","principalactivities":"於中國從事生物制藥產品的開發、生產、市場推廣及銷售。","website":"http://www.3sbio.com"},"managerinfo":[],"investorinfo":[{"institutionname":"BlackRock Funds","shareholding":"34,064,500.0","percentage":1.41,"ReleaseDate":"2015-12-11 00:00:00","relatedparty":"BlackRock, Inc.","subsidiary":["BlackRock Funds"],"InverstorType":"基金"},{"institutionname":"GIC Private Limited","shareholding":"25,551,000.0","percentage":1.05,"ReleaseDate":"2015-12-11 00:00:00","relatedparty":"","subsidiary":[],"InverstorType":"公司"},{"institutionname":"Lilly Asia Ventures Fund III, L.P.","shareholding":"25,551,000.0","percentage":1.05,"ReleaseDate":"2015-12-11 00:00:00","relatedparty":"LAV Corporate G.P., Ltd.","subsidiary":["Lilly Asia Ventures Fund III, L.P."],"InverstorType":"基金"},{"institutionname":"新華資產管理(香港)有限公司","shareholding":"17,034,000.0","percentage":0.7,"ReleaseDate":"2015-12-11 00:00:00","relatedparty":"新華人壽保險股份有限公司","subsidiary":["新華資產管理(香港)有限公司","新華資本管理有限公司"],"InverstorType":"公司"}],"TotalShareholdingPercentage":5.26},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":513}